Compositions for Treating Acute respiratory distress syndrome Comprising Exosome Derived from Stem Cell Treated with Thrombin
Thrombin-treated stem cell-derived exosomes address the limitations of traditional stem cell therapies by significantly reducing inflammatory cytokines, offering a promising treatment for infectious diseases like ARDS.
Patent Information
- Application Number
- KR1020210161294
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-11-26
- Filing Date
- 2021-11-22
- Publication Date
- 2026-11-10
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for infectious diseases, particularly severe conditions like ARDS, are limited, and stem cell therapies face challenges such as tumorogenicity, vascular obstruction, rejection issues, and high production costs, while exosomes derived from stem cells offer a promising alternative with reduced risks and enhanced therapeutic potential.
A pharmaceutical composition utilizing thrombin-treated stem cell-derived exosomes as an active ingredient, which are administered to prevent or treat infectious diseases, including ARDS, by reducing inflammatory cytokine production.
Thrombin-treated stem cell-derived exosomes effectively decrease inflammatory cytokine expression, providing a safe and cost-effective treatment for infectious diseases by leveraging their anti-inflammatory properties.
Smart Images

Figure 112021134365919-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of infectious diseases comprising exosomes derived from thrombin-treated stem cells as an active ingredient, a pharmaceutical preparation containing the same, and a method for manufacturing the same. Background Technology
[0002] Infectious diseases are conditions caused by microbial infections, such as those by bacteria, viruses, fungi, and parasites, and are subdivided into various types depending on the type of microorganism involved. Microbial infections can affect specific parts of the body (localized infections) or the entire body (systemic infections); localized infections include, for example, abscesses and bladder infections, while severe systemic infections include sepsis or septic shock. Symptoms of infection may include fever, rapid pulse, rapid breathing, anxiety, and confusion; in most cases, the effects of the infection resolve when it is effectively treated.
[0003] Acute Respiratory Distress Syndrome (ARDS), which develops as one of the major causes of severe infections such as the aforementioned sepsis, is triggered when substances such as cytokines are released into the bloodstream due to infection or bodily injury and reach the lungs, causing severe inflammation. Research results have reported that various inflammatory cytokines are involved in initiating and amplifying inflammatory responses in ARDS, and it is also known that the balance between inflammatory and anti-inflammatory mediators plays an important role (Korean Journal of Internal Medicine, Vol. 68, No. 5, Issue No. 537, 2005). This disease typically manifests within hours to days of exposure to the causative agent, presenting with severe respiratory distress to the point where life cannot be sustained without a ventilator. Generally, treatment involves intensive care including mechanical ventilation using a ventilator; however, this is not a fundamental cure but merely supports the patient's breathing during the time required for the lungs to heal. Although various attempts have been made to reduce patient mortality, mechanical ventilation remains virtually the only effective method currently available. In addition, antibiotic treatment is administered when accompanied by infection; however, since it is an intractable disease with almost no effective treatments available to date, the development of therapeutic agents is urgent.
[0004] Meanwhile, stem cells are known to possess pluripotency and are involved in tissue regeneration, healing, and immune responses. Consequently, efforts have been made to utilize these characteristics to isolate and culture mesenchymal stem cells from sources such as umbilical cord blood and bone marrow, with the aim of developing them into therapeutic agents for various diseases and symptoms. However, cell therapy utilizing these stem cells themselves has limitations, including the potential for tumorogenicity due to DNA transfer, the risk of vascular obstruction or myocardial infarction caused by their large size, rejection issues arising from surface antigens during allogeneic transplantation, as well as complex manufacturing processes and high production costs.
[0005] Exosomes are small membrane-bound vesicles (approximately 30–100 nm in diameter) secreted by various cells. Electron microscopy studies have observed that they do not detach directly from the plasma membrane but rather originate from specific intracellular compartments called multivesicular bodies (MVBs) before being released and secreted outside the cell. In other words, when the fusion of the multivesicular body and the plasma membrane occurs, the vesicles are released into the extracellular environment, which is called an exosome. Although the specific molecular mechanism by which these exosomes are produced has not been definitively elucidated, it is known that not only red blood cells but also various types of immune cells—including B lymphocytes, T lymphocytes, dendritic cells, platelets, and macrophages—as well as tumor cells and stem cells, produce and secrete exosomes while alive.
[0006] In particular, exosomes derived from stem cells are known to play a role in intercellular communication as they contain nuclear components as well as receptors and proteins. Furthermore, since these stem cell-derived exosomes contain relatively less animal serum compared to stem cells, the risk of zoonosis caused by animal serum infection can also be eliminated. Considering these characteristics of exosomes, cell therapy using exosomes is expected to become a new paradigm capable of overcoming the limitations of existing stem cell therapies. The problem to be solved
[0007] As a result of research efforts to apply stem cell-derived exosomes to infectious diseases, the inventors created an infectious environment by treating Raw 264.7 cells with lipopolysaccharide (LPS) and then treated them with stem cell-derived exosomes treated with thrombin, LPS, and TNF, respectively. Consequently, they confirmed an excellent anti-inflammatory effect in the group treated with thrombin-treated stem cell-derived exosomes through a reduction in the production of inflammatory cytokines, and based on this, the present invention was completed.
[0008] Accordingly, the present invention aims to provide a pharmaceutical composition for the prevention or treatment of infectious diseases, comprising thrombin-treated stem cell-derived exosomes as an active ingredient.
[0009] In addition, the present invention has another objective of providing a pharmaceutical preparation for treating infectious diseases comprising the above pharmaceutical composition.
[0010] In addition, the present invention has another objective of providing a method for manufacturing the above pharmaceutical composition.
[0012] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art from the description below. means of solving the problem
[0013] To achieve the above-mentioned objectives of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of infectious diseases comprising thrombin-treated stem cell-derived exosomes as an active ingredient.
[0014] In one embodiment of the present invention, the stem cell may be selected from the group consisting of mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells, multipotent stem cells, and amniotic epithelial cells.
[0015] In another embodiment of the present invention, the mesenchymal stem cells may be derived from the umbilical cord, umbilical cord blood, bone marrow, fat, muscle, skin, amniotic membrane, placenta, or other tissues.
[0016] In another embodiment of the present invention, the infectious disease may be selected from the group consisting of infectious lung disease, sepsis, and systemic inflammatory response syndrome.
[0017] In another embodiment of the present invention, the infectious lung disease may be acute respiratory distress syndrome (ARDS).
[0018] In another embodiment of the present invention, the pharmaceutical composition may further include an auxiliary component selected from the group consisting of a culture medium, cytokines, growth factors, and genes.
[0019] In addition, the present invention provides a pharmaceutical preparation for treating infectious diseases comprising the above pharmaceutical composition.
[0020] In one embodiment of the present invention, the pharmaceutical formulation may be an injectable formulation, an infusion formulation, a spray formulation, a liquid formulation, or a patch formulation.
[0021] In addition, the present invention provides a method for preparing the pharmaceutical composition comprising the following steps.
[0022] (a) Step of treating with thrombin after stem cell culture;
[0023] (b) a step of isolating exosomes from the culture medium of step (a); and
[0024] (c) A step of preparing a composition containing the exosomes isolated in step (b) as an active ingredient.
[0025] In one embodiment of the present invention, the thrombin of step (a) may be included in the medium at a concentration of 1-1000 unit / ml.
[0026] In another embodiment of the present invention, the exosomes of step (b) may be separated by centrifuging at 3,000-100,000 g for 10 minutes to 5 hours.
[0027] In addition, the present invention provides a method for preventing or treating an infectious disease, comprising the step of administering the above pharmaceutical composition to an individual.
[0028] In addition, the present invention provides the use of the above pharmaceutical composition for the prevention or treatment of infectious diseases. Effects of the invention
[0029] The inventors have specifically confirmed that exosomes isolated from thrombin-treated stem cells significantly reduce the expression of inflammatory cytokines under conditions of inflammation compared to cases where they are not treated with thrombin or treated with other substances. Therefore, it is expected that the thrombin-treated stem cell-derived exosomes according to the present invention can be usefully utilized in related fields for the improvement or treatment of various infectious diseases caused by immune or inflammatory responses induced by infection. Brief explanation of the drawing
[0030] Figure 1 shows the results of measuring the concentrations of inflammatory cytokines TNF-α and IL-1β in the cell culture medium after treating RAW 264.7 cells with LPS, then treating the cells with exosomes isolated from untreated stem cells (naive), and then treating the cells with exosomes isolated from stem cells treated with LPS, TNF, and thrombin, respectively. Figure 2 shows the results of measuring the concentrations of inflammatory cytokines (TNF-α, IL-1β, IL-6) in a saline administration group (control group, ARDS) and a group administered thrombin-treated stem cell-derived exosomes (ARDS-exo) in an animal model of an infectious disease. Specific details for implementing the invention
[0031] The inventors confirmed the excellent anti-inflammatory effect of thrombin-treated stem cell-derived exosomes in an infectious environment, and based on this, completed the present invention.
[0032] Accordingly, the present invention provides a pharmaceutical composition for the prevention or treatment of infectious diseases, comprising thrombin-treated stem cell-derived exosomes as an active ingredient.
[0033] The term “thrombin” used in the present invention refers to a proteolytic enzyme involved in blood coagulation that catalyzes the reaction of hydrolyzing soluble fibrinogen in the blood and converting it into insoluble fibrin. The present invention demonstrates the function of effectively enhancing the therapeutic effect of exosomes isolated from said stem cells on infectious diseases when treated with said stem cells.
[0034] As used in the present invention, the term “stem cell” refers to an “undifferentiated cell” that possesses the ability to differentiate but has not yet undergone differentiation, and is a cell capable of self-replication and differentiating into two or more different types of cells. The stem cells of the present invention may be autologous or allogeneic stem cells, and may be derived from any type of animal, including humans and non-human mammals.
[0035] In the present invention, the stem cells of the present invention include embryonic stem cells or adult stem cells, and preferably may be adult stem cells. The adult stem cells may be mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells, or pluripotent stem cells, and preferably may be mesenchymal stem cells, but are not limited thereto.
[0036] The above mesenchymal stem cells may be mesenchymal stem cells derived from the umbilical cord, umbilical cord blood, bone marrow, fat, muscle, skin, amniotic membrane, placenta, and other tissues, but are not limited thereto.
[0037] The term “exosome” as used in the present invention refers to a small membrane-structured vesicle (approximately 30-100 nm in diameter) secreted from various cells, and refers to a vesicle that is released into the extracellular environment after the fusion of a polycystic body and a plasma membrane. The exosome includes naturally secreted or artificially secreted exosomes. Since exosome-based therapeutic agents are cell-free preparations, they do not contain DNA, thus having a low risk of carcinogenesis. Furthermore, because they lack cell surface antigens, they are safe as there is no problem with transplant rejection reactions. Additionally, as they are isolated materials rather than cells, they can be developed as off-the-shelf products, which has the advantage of reducing manufacturing costs.
[0038] As used in the present invention, the term “prevention” refers to any act of suppressing an infectious disease or delaying its onset by administering a pharmaceutical composition according to the present invention.
[0039] As used in the present invention, the term “treatment” refers to any act in which symptoms of an infectious disease are improved or beneficially altered by the administration of a pharmaceutical composition according to the present invention.
[0040] In the present invention, “infectious disease” includes all diseases caused by microbial infections such as bacteria, viruses, fungi, and parasites, and preferably may be diseases caused by immune and inflammatory responses through infection, and more preferably may be selected from the group consisting of infectious lung disease, sepsis, and systemic inflammatory response syndrome, and most preferably infectious lung disease may be acute respiratory distress syndrome.
[0041] The above-mentioned acute respiratory distress syndrome (ARDS) is an intractable disease with few treatments available. It is primarily caused by severe infections or pneumonia, but can also be caused by physical injuries, other organ problems, etc. As a result of acute respiratory distress syndrome, blood oxygen levels decrease, and specific cytokines secreted by damaged lung cells and white blood cells leak into the bloodstream, potentially causing inflammation and complications in other organs.
[0042] The aforementioned sepsis is a systemic response to microbial infection, and the causes of sepsis / septic shock include various bacteria, particularly E. coli ( E. coli ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ), Klebsiella bacteria( Klebsiella pneumoniae It is known that the frequency of Gram-negative bacteria is high. Pathophysiologically, the entire immune system, including various blood cells, endothelial cells, and bone marrow, is activated to eliminate infectious agents that have invaded from the outside, and it has been reported that major organs are damaged by many mediators, such as cytokines secreted during this process.
[0043] The aforementioned systemic inflammatory response syndrome refers to a clinical condition in which two or more of the following symptoms caused by inflammation are present simultaneously: fever, hypothermia, rapid pulse, rapid respiration, and abnormally high white blood cell counts.
[0044] The pharmaceutical composition of the present invention may further include an auxiliary component selected from the group consisting of a culture medium, cytokines, growth factors, and genes.
[0045] The pharmaceutical composition of the present invention may be used alone or in combination with other therapeutic agents for the treatment of infectious diseases.
[0046] The pharmaceutical composition of the present invention comprises exosomes derived from thrombin-treated stem cells as an active ingredient and may further comprise a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is one commonly used in formulations and includes, but is not limited to, saline solution, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes, etc., and may further include other conventional additives such as antioxidants and buffers as needed. Additionally, diluents, dispersants, surfactants, binders, lubricants, etc., may be added to formulate the composition into injectable formulations such as aqueous solutions, suspensions, and emulsions, or into pills, capsules, granules, or tablets. Regarding suitable pharmaceutically acceptable carriers and formulations, the composition may preferably be formulated according to each component using the methods disclosed in the literature of Remington.
[0047] The pharmaceutical composition of the present invention may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method, and the dosage may be appropriately selected by those skilled in the art, although it depends on the patient's condition and body weight, the severity of the disease, the form of the drug, the route of administration, and the time.
[0048] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, a “pharmaceutically effective amount” means an amount sufficient to treat or diagnose a disease with a reasonable benefit / risk ratio applicable to medical treatment or diagnosis, and the effective dose level may be determined based on factors including the patient’s disease type and severity, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. Other pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by considering all of the above-mentioned factors, and this can be easily determined by a person skilled in the art.
[0049] Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, gender, condition, body weight, absorption rate, inactivation rate, and excretion rate of the active ingredient in the body, the type of disease, and concomitant drugs. Generally, 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight, may be administered daily or every other day, or divided into 1 to 3 doses per day. However, since the dosage may be increased or decreased depending on the route of administration, severity of obesity, gender, body weight, age, etc., the above dosage does not limit the scope of the present invention in any way.
[0050] In addition, the present invention provides a pharmaceutical preparation for treating infectious diseases comprising the above pharmaceutical composition.
[0051] The above pharmaceutical preparation may be injectable, infusion, spray, liquid, or patch formulations, but is not limited thereto, and a person skilled in the art may select and use a formulation suitable for the treatment of the infectious disease.
[0052] In the present invention, through specific examples, it was confirmed that stem cell-derived exosomes treated with thrombin have an excellent therapeutic effect on infectious diseases.
[0053] In one embodiment of the present invention, umbilical cord blood-derived mesenchymal stem cells were treated with thrombin and cultured, and then exosomes were isolated by centrifugation (see Example 1).
[0054] In another embodiment of the present invention, to evaluate the therapeutic effect of the exosomes on infectious diseases, Raw 264.7 mouse-derived macrophages were treated with LPS, and then exosomes isolated from untreated stem cells, and exosomes isolated from stem cells treated with LPS, TNF, and thrombin, respectively, were treated to the cells. After measuring the concentrations of the inflammatory cytokines TNF-α and IL-1β in the cell culture medium, it was confirmed that only the group treated with thrombin-treated stem cell-derived exosomes showed a significant decrease in the concentrations of the two cytokines (see Example 2-1).
[0055] In addition, in an animal model of an infectious disease, it was found that the group administered thrombin-treated stem cell-derived exosomes (ARDS-exo) showed a statistically significant decrease in the concentrations of inflammatory cytokines such as TNF-α, IL-1β, and IL-6 compared to the control group (saline administration group) (see Example 2-2).
[0056] Accordingly, as another aspect of the present invention, the present invention provides a method for preparing the pharmaceutical composition comprising: (a) a step of treating with thrombin after stem cell culture; (b) a step of isolating exosomes from the culture medium of step (a); and (c) a step of preparing a composition containing the exosomes isolated in step (b) as an active ingredient.
[0057] In the present invention, there are no specific limitations on the thrombin treatment concentration as long as it is a concentration suitable for enhancing the efficacy of stem cells / exosomes, but it is preferable to include it in the medium at a concentration of 1-1000 unit / ml.
[0058] In the present invention, there are no limitations on the method for isolating exosomes. For example, they can be isolated in a culture medium using methods such as centrifugation, ultracentrifugation, filtration by a filter, gel filtration chromatography, free-flow electrophoresis, capillary electrophoresis, separation using a polymer, and combinations thereof. Preferably, centrifugation / ultracentrifugation may be used. At this time, centrifugation / ultracentrifugation is preferably performed at 4°C and 3,000-100,000 g for 10 minutes to 5 hours.
[0059] The medium used for cell culture in the present invention is an ex vivo medium containing elements essential for cell growth and proliferation, such as sugars, amino acids, various nutrients, serum, growth factors, and minerals. in vitro ) refers to a mixture for the growth and proliferation of cells such as stem cells. The media that can be used in the present invention include, but are not limited to, commercially manufactured media or artificially synthesized media such as DMEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI1640, DMEM / F-10 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-10), DMEM / F-12 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12), α-MEM (α-Minimal Essential Medium), G-MEM (Glasgow's Minimal Essential Medium), IMDM (Isocove's Modified Dulbecco's Medium), and KnockOut DMEM.
[0060] In another aspect of the present invention, the present invention provides a method for preventing or treating an infectious disease comprising the step of administering to an individual a pharmaceutical composition containing exosomes derived from thrombin-treated stem cells as an active ingredient.
[0061] In the present invention, the term “individual” refers to a subject requiring treatment for a disease, and more specifically, to mammals such as humans or non-human primates, mice, rats, dogs, cats, horses, and cattle.
[0062] In addition, the present invention provides the use of the above pharmaceutical composition for the prevention or treatment of infectious diseases.
[0064] Preferred embodiments are presented below to aid in understanding the present invention. However, the following embodiments are provided merely to facilitate a better understanding of the invention, and the scope of the invention is not limited by the following embodiments.
[0066] [Example]
[0067] Example 1. Induction of Exosome Secretion in Stem Cells by Thrombin Treatment
[0068] Human umbilical cord blood-derived mesenchymal stem cells (3×10⁶ 5 The cells were dispensed into a 100 mm culture dish (orange scientific cat# 4450200) and cultured for one week. After confirming that the cells in the culture dish had saturated with cells, the medium was replaced with serum-free culture medium (MEM alpha media) diluted with 50 unit / ml thrombin (REYON Pharmaceutical. Co., LTD) and cultured again for 6 hours. Subsequently, the culture medium was divided into centrifuge tubes and centrifuged at 4°C and 6,000 rpm for 30 minutes, and the supernatant was transferred to a new tube to remove cell debris. Then, the supernatant was ultracentrifuged at 4°C and 100,000 rpm for 2 to 4 hours, and the supernatant was further removed to obtain exosomes.
[0070] Example 2. Confirmation of anti-inflammatory and anti-infectious disease effects by thrombin-treated stem cell-derived exosomes
[0071] The inventors conducted the following experiment to determine whether thrombin-treated stem cell-derived exosomes can treat diseases caused by infection, such as acute respiratory distress syndrome (ARDS), through anti-inflammatory effects.
[0073] 2-1. in vitro experiment
[0074] RAW 264.7 mouse-derived macrophages were cultured, and then the cells were activated by treating them with lipopolysaccharide (LPS), which is found in the membranes of Gram-negative bacteria and is one of the external immune inducers. Subsequently, exosomes isolated from untreated stem cells, or exosomes isolated from stem cells treated with LPS, TNF, and thrombin, respectively, were treated, and the concentrations of representative inflammation-inducing cytokines, TNF-α (tumor necrosis factor-α) and IL-1β (Interleukin 1 beta), were measured in the culture medium.
[0075] As a result, as can be seen in Figure 1, the concentrations of TNF-α and IL-1β in the culture medium increased in the control group (NC) of RAW 264.7 cells treated only with LPS. In contrast, the concentrations of the cytokines in the culture medium decreased in the group treated with untreated stem cell-derived exosomes (naive) and in the group treated with stem cell-derived exosomes treated with LPS or TNF, respectively, compared to the control group. In addition, it was confirmed that the production of the two cytokines decreased statistically significantly, particularly in the case of stem cell-derived exosomes treated with thrombin.
[0077] 2-2. in vivo Experiment (infectious disease animal model)
[0078] To prepare an animal model of an infectious disease (ARDS mouse model), Rumpun and ketamine saline were diluted and administered intraperitoneally to mice (16–24 weeks old) to anesthetize them, then a catheter was inserted into the airway, and E. coli ( E.coli 0.05cc was administered into the airway using a 1ml syringe.
[0079] After administering E. coli, the mice were divided into a saline-administered group (ARDS) and a thrombin-treated stem cell-derived exosome (hereinafter referred to as exosome)-administered group (ARDS-exo). Saline and exosomes were administered to each group, respectively. After 24 hours, the mice were sacrificed by inhalation anesthesia using Ifrane solution. The trachea was then exposed at the neck of the mice, a catheter was inserted into the trachea, and it was secured with sutures. Saline was injected into the lungs using a syringe, and BAL (Bronchoalveolar Lavage) Fluid was carefully collected from the lungs. The collected BAL fluid was centrifuged to remove cells and bacteria, and the supernatant was frozen and stored at -70°C until biochemical analysis was performed.
[0080] After slowly thawing the BAL fluid stored at -70℃ at 4℃, the concentrations of inflammatory cytokines (TNF-α, IL-1β, IL-6) were measured using a multiplex cytokine kit according to the manufacturer's protocol.
[0081] As a result, as can be seen in Figure 2, in an infectious disease mouse model, it was found that the concentrations of inflammatory cytokines such as TNF-α, IL-1β, and IL-6 were statistically significantly (t-test) reduced in the exosome administration group (ARDS-exo) compared to the saline administration group (ARDS).
[0083] Through the above results, it can be seen that exosomes derived from thrombin-treated stem cells have excellent anti-inflammatory and therapeutic effects on infectious diseases, which demonstrates that the exosomes can be used to treat various diseases caused by inflammation triggered by immune responses, particularly infectious diseases, through their anti-inflammatory effects.
[0085] The description of the invention set forth above is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.
Claims
Claim 1 A pharmaceutical composition for the prevention or treatment of acute respiratory distress syndrome (ARDS), comprising exosomes derived from thrombin-treated stem cells as an active ingredient, wherein the composition is for administration to the lungs, and the exosomes reduce the levels of IL-6, TNF-α, and IL-1β in lung tissue upon thrombin treatment. Claim 2 A pharmaceutical composition according to claim 1, characterized in that the stem cell is selected from the group consisting of mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells, multipotent stem cells, and amniotic epithelial cells. Claim 3 A pharmaceutical composition according to claim 2, characterized in that the mesenchymal stem cells are derived from the umbilical cord, umbilical cord blood, bone marrow, fat, muscle, skin, amniotic membrane, or placenta. Claim 4 delete Claim 5 delete Claim 6 A pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition further comprises an auxiliary component selected from the group consisting of a culture medium, a cytokine, a growth factor, and a gene. Claim 7 A pharmaceutical preparation for treating acute respiratory distress syndrome (ARDS) comprising the composition of claim 1, wherein the preparation is for administration to the lungs. Claim 8 A pharmaceutical preparation according to claim 7, characterized in that the above pharmaceutical preparation is an injectable formulation, an infusion formulation, a spray formulation, a liquid formulation, or a patch formulation. Claim 9 delete Claim 10 delete Claim 11 delete
Citation Information
Patent Citations
Composition for treating inflammatory disease of brain comprising stem cell-derived exosome
KR101661847B1
